Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Biomea Fusion has initiated two Phase II clinical trials (COVALENT-211 and COVALENT-212) testing their drug icovamenib in distinct type 2 diabetes populations failing existing standard-of-care treatments. Early studies showed promising and durable glycemic control benefits, prompting advancement to larger, targeted studies with topline data expecte…